MSP Recovery (LIFW) Competitors

$1.16
-0.06 (-4.92%)
(As of 02:04 PM ET)

LIFW vs. SY, OMER, AKYA, XFOR, RANI, OGI, ZVRA, MASS, MACK, and RIGL

Should you be buying MSP Recovery stock or one of its competitors? The main competitors of MSP Recovery include So-Young International (SY), Omeros (OMER), Akoya Biosciences (AKYA), X4 Pharmaceuticals (XFOR), Rani Therapeutics (RANI), Organigram (OGI), Zevra Therapeutics (ZVRA), 908 Devices (MASS), Merrimack Pharmaceuticals (MACK), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "medical" sector.

MSP Recovery vs.

So-Young International (NASDAQ:SY) and MSP Recovery (NASDAQ:LIFW) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

So-Young International has a net margin of 1.37% compared to So-Young International's net margin of -731.32%. MSP Recovery's return on equity of 0.81% beat So-Young International's return on equity.

Company Net Margins Return on Equity Return on Assets
So-Young International1.37% 0.81% 0.65%
MSP Recovery -731.32%-12.92%-6.63%

In the previous week, MSP Recovery had 6 more articles in the media than So-Young International. MarketBeat recorded 6 mentions for MSP Recovery and 0 mentions for So-Young International. So-Young International's average media sentiment score of 0.19 beat MSP Recovery's score of 0.13 indicating that MSP Recovery is being referred to more favorably in the news media.

Company Overall Sentiment
So-Young International Neutral
MSP Recovery Neutral

So-Young International has higher revenue and earnings than MSP Recovery.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
So-Young International$210.99M0.59$3M$0.0341.51
MSP Recovery$7.70M21.09-$56.35MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
So-Young International
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
MSP Recovery
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

So-Young International has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, MSP Recovery has a beta of -2.01, indicating that its share price is 301% less volatile than the S&P 500.

So-Young International received 55 more outperform votes than MSP Recovery when rated by MarketBeat users.

CompanyUnderperformOutperform
So-Young InternationalOutperform Votes
55
64.71%
Underperform Votes
30
35.29%
MSP RecoveryN/AN/A

35.3% of So-Young International shares are owned by institutional investors. Comparatively, 3.8% of MSP Recovery shares are owned by institutional investors. 16.7% of So-Young International shares are owned by company insiders. Comparatively, 19.4% of MSP Recovery shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

So-Young International beats MSP Recovery on 8 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIFW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIFW vs. The Competition

MetricMSP RecoveryData processing & preparation IndustryMedical SectorNASDAQ Exchange
Market Cap$162.37M$3.72B$4.80B$7.47B
Dividend YieldN/A2.63%5.47%3.97%
P/E RatioN/A16.10188.7016.65
Price / Sales21.096.962,570.7482.50
Price / Cash0.3342.0031.6927.23
Price / Book0.116.784.664.30
Net Income-$56.35M$47.67M$101.62M$213.07M
7 Day Performance24.46%3.03%-0.21%0.67%
1 Month Performance54.05%-4.47%-5.70%-4.11%
1 Year Performance-93.64%-3.03%9.61%6.09%

MSP Recovery Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SY
So-Young International
0 of 5 stars
$1.15
-4.2%
N/A-52.7%$114.13M$210.99M38.351,573Positive News
OMER
Omeros
0 of 5 stars
$3.64
+6.1%
N/A-45.6%$210.90MN/A-1.94196
AKYA
Akoya Biosciences
2.9455 of 5 stars
$4.30
-1.6%
$9.07
+111.0%
-46.6%$211.30M$96.63M-2.91330News Coverage
Positive News
XFOR
X4 Pharmaceuticals
4.2867 of 5 stars
$1.22
-3.9%
$3.00
+145.9%
-6.2%$213.28MN/A-2.0393Positive News
RANI
Rani Therapeutics
0.932 of 5 stars
$4.16
+4.0%
$14.00
+236.5%
+38.1%$208.67M$2.72M-3.13140Gap Down
OGI
Organigram
0 of 5 stars
$2.07
-1.0%
N/A-5.0%$213.62M$120.01M-2.59984
ZVRA
Zevra Therapeutics
1.2948 of 5 stars
$4.92
+4.0%
$19.50
+296.3%
-22.0%$213.68M$27.46M-3.8132
MASS
908 Devices
2.2324 of 5 stars
$6.33
-9.3%
$14.00
+121.2%
-28.8%$208.32M$50.23M-5.60230News Coverage
MACK
Merrimack Pharmaceuticals
0 of 5 stars
$14.72
-0.1%
N/A+20.8%$213.88MN/A-184.00426
RIGL
Rigel Pharmaceuticals
1.1115 of 5 stars
$1.22
-2.4%
$5.81
+376.4%
-5.0%$213.96M$116.88M-8.13147

Related Companies and Tools

This page (NASDAQ:LIFW) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners